Scipher to use proprietary patient molecular data analyzed by its Spectra^TM platform to identify novel drug targets. TARA Biosystems to progress selected targets in its Biowire^TM II drug discovery platform for cardiac laminopathies. Partnership set to reduce target discovery and validation from years down …

NEW YORK, NY - (EurekAlert) - VantAI and TARA Biosystems today announced the launch of a biology-driven, AI-enabled collaboration for accelerated cardiac drug development. The partnership will leverage TARA’s state-of-the-art in vitro human …

NEW YORK, NY - (EurekAlert) - TARA Biosystems today reported study results demonstrating the ability of TARA’s in vitro human cardiac models to reproduce drug responses similar to those observed in humans. Appearing …

NEW YORK, NY - (BUSINESS WIRE) - TARA Biosystems, Inc., a company generating in vitro human biology to increase the success of cardiac disease drug discovery and development, today announced a $10 million Series A2 …

Tuesday March 3, 2020 – Keystone, Colorado.  TARA Biosystems Inc. today reported data showcasing its Biowire™ II as a platform for heart failure drug discovery.  Speaking at this year's Keystone …